Contact Us
Drug Search Results
More Filters [+]

Ganitumab

Alternative Names: ganitumab, amg-479, amg 479, amg479
Latest Update: 2024-11-08
Latest Update Note: Clinical Trial Update

Product Description

Amgen is developing Ganitumab (AMG 479). It is a fully human anti-insulin-like growth factor receptor type I monoclonal antibody which inhibits the growth and survival of pancreatic carcinoma cells. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19366899/)

Mechanisms of Action: IGF-1 Blocker

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ganitumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Adenocarcinoma|Bone Cancer|Endocrine Gland Cancer|Pancreatic Cancer|Peripheral Neuroectodermal Tumors, Primitive|Sarcoma, Ewing|Primitive Neuroectodermal Tumors|Bone Marrow Diseases

Phase 2: Colorectal Cancer|Neuroendocrine Tumors|Carcinoid Tumor|Peritoneal Cancer|Ovarian Cancer|Primitive Neuroectodermal Tumors|Fallopian Tube Cancer|Gastrointestinal Cancer|Breast Cancer|Islet Cell Adenoma|Pancreatic Cancer|Non-Small-Cell Lung Cancer|Lymphoma|Sarcoma|Desmoplastic Small Round Cell Tumor|Adenocarcinoma|Sarcoma, Ewing|Melanoma|Small Cell Sarcoma|Small Cell Lung Cancer|Embryonal Rhabdomyosarcoma|Alveolar Rhabdomyosarcoma|Squamous Cell Carcinoma

Phase 1: Sarcoma|Intestinal Cancer|Pancreatic Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Colorectal Cancer|Ovarian Cancer|Lymphoma, Non-Hodgkin|Prostate Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT04129151

P2

Completed

Sarcoma, Ewing

2022-12-15

17-C-0049

P2

Terminated

Alveolar Rhabdomyosarcoma|Embryonal Rhabdomyosarcoma

2021-09-15

NCI-2014-02380

P3

Active, not recruiting

Peripheral Neuroectodermal Tumors, Primitive|Bone Marrow Diseases|Primitive Neuroectodermal Tumors|Sarcoma, Ewing

2021-03-31

AMG 479

P2

Completed

Non-Small-Cell Lung Cancer|Colorectal Cancer|Carcinoid Tumor|Lymphoma|Sarcoma

2020-02-05

Recent News Events

Date

Type

Title

10/30/2023

PubMed

 Results from the Children's Oncology Group phase III trial of a monoclonal antibody against the insulin-like growth factor-1 receptor in patients with newly diagnosed metastatic Ewing sarcoma.

09/01/2023

PubMed

 Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma.

07/01/2023

PubMed

 Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma.

06/23/2023

News Article

 Global Ewing Sarcoma Therapeutics Research Report 2023 Featuring Abbott, AbbVie, Amgen, AstraZeneca, Bausch, Bayer, BMS, Eli Lilly, Merck, AbbVie, GSK, Johnson & Johnson, Novartis, and Sanofi

03/23/2021

News Article

 Transcenta Announces Appointments of Dr. Xichen Zhang as Senior Vice President of Manufacturing and Dr. Steven Yu as Senior Vice President of DMPK and Translational Science

11/07/2019

News Article

 Global Neuroendocrine Tumors (NETs) Market Insights, Epidemiology and Market Forecasts, 2017-2018 & 2019-2028 - ResearchAndMarkets.com

11/07/2019

News Article

 Global Neuroendocrine Tumors (NETs) Market Report 2019

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions